Available clinical trials are below. Click the + sign to expand and review details about their purpose, eligibility criteria, and contact information for study staff. For some studies, you will find a link to ClinicalTrials.gov, where you can explore more information about each study.

AstraZeneca D6900C00003 / GOG 3110

Study Phase: Phase III

Condition(s): Advanced or metastatic, B7-H4 expressing
A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) Monotherapy versus Physician’s Choice of Chemotherapy in Participants with B7-H4-Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum-Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy (BLUESTAR-Endometrial01)

ClinicalTrials.gov NCT ID: NCT07044336

You can view the full clinical description on ClinicalTrials.gov.

View Full Description
clinical-trials-profile

Janine Schippang

Primary Contact - Study Coordinator

484-658-1790
janineL.schippang@sluhn.org

profile_sarah-huepenbecker

Sarah P. Huepenbecker, MD

Physician - Principal Investigator

NRG - NRG-GY026

Study Phase: Phase II/III - Drug

Condition(s): Stage I-IV endometrial cancer
Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Herceptin Hylecta or Pertuzumab, Trastuzumab and PHESGO in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma

ClinicalTrials.gov NCT ID: NCT05256225

You can view the full clinical description on ClinicalTrials.gov.

View Full Description
clinical-trials-profile

Janine Schippang

Primary Contact - Study Coordinator

484-658-1790
janineL.schippang@sluhn.org

profile_nicholas-taylor

Nicholas Taylor, MD

Physician - Principal Investigator

Merck MK2870-33

Study Phase: Phase III - drug

Condition(s): Stage III or IV endometrial cancer
A Phase 3 Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan in Combination with Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants with Mismatch Repair Proficient Endometrial Cancer (TroFuse-033)

ClinicalTrials.gov NCT ID: NCT06952504

You can view the full clinical description on ClinicalTrials.gov.

View Full Description
clinical-trials-profile

Janine Schippang

Primary Contact - Study Coordinator

484-658-1791
janineL.schippang@sluhn.org

profile_sarah-huepenbecker

Sarah P. Huepenbecker, MD

Physician - Principal Investigator

To inquire if you're eligible for a clinical trial, contact: (484) 658-5080, or click here to complete a clinical trial inquiry form.

Cancer Ribbon

Transforming lives through philanthropy

Supporting clinical trials and research can help us create a future where advanced health care is accessible and equitable for everyone. Together, we can transform lives and improve health care for generations to come.

Donate today